Soluble CLCA-1 and antagonists to CLCA-1
AssigneeWyeth
InventorsAndrew J. Long, Clive R. Wood, Michael Bowman, Samuel J. Goldman, Joseph P. Sypek
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.
Claims15
A method of treating a subject having a disease or condition wherein CLCA1 expression or activity is elevated in the subject compared to an individual without the disease or condition, said method comprising administering to said subject a therapeutically effective amount of at least one agent which inhibits or prevents soluble CLCA1 association with a cell membrane molecule, thereby treating the disease or condition.
A method of isolating CLCA1 comprising obtaining a fluid from a subject;
- contacting said fluid with a specific binding partner of CLCA1 such that a complex between CLCA1 and the specific binding partner forms;
- isolating the complex of CLCA1 and the specific binding partner of CLCA1 from said fluid;
- and disrupting the complex of CLCA1 and the specific binding partner of CLCA1 such that CLCA1 is isolated.
Dependencies are inferred from the claim text.